Sanofi and MannKind Corpration have entered into a worldwide exclusive licensing agreement for development and commercialization of Afrezza® (insulin human) Inhalation Powder, a new rapid-acting inhaled insulin therapy for adults with type 1 and type 2 diabetes.The companies plan to launch Afrezza in the United States in the first quarter of 2015.